Physician profile
Melissa Renzi
NPI 1912498767
$7,752.69
in general payments reported to CMS, 2019-2025
29 companies · $2,721 in 2025
The $2,721 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.20 · 2022: $305 · 2023: $2,390 · 2024: $2,322 · 2025: $2,721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,061 · Education: $373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,060.65 |
| Education | $372.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,493.72 | 2022-2025 | |
| Janssen Biotech, INC. | $1,379.83 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Sun Pharmaceutical Industries INC. | $925.14 | 2023-2025 | Ilumya, Absorica Ld, Winlevi |
| Genzyme Corporation | $580.45 | 2022-2025 | |
| Leo Pharma INC. | $534.30 | 2024-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $475.75 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $437.00 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $311.78 | 2022-2025 | Dupixent, Libtayo |
| Incyte Corporation | $238.89 | 2022-2023 | Opzelura |
| Amgen INC. | $193.26 | 2023-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $190.33 | 2024-2025 | Nemluvio, Aklief |
| Sanofi-Aventis U.S. LLC | $164.99 | 2023-2025 | |
| Pfizer INC. | $163.71 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $126.48 | 2023-2025 | Sotyktu |
| Janssen Scientific Affairs, LLC | $69.30 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $68.92 | 2024-2025 | Cabtreo |
| Arcutis Biotherapeutics, INC. | $59.99 | 2024-2025 | Zoryve |
| Organon LLC | $52.46 | 2025 | Vtama |
| Verrica Pharmaceuticals INC. | $42.98 | 2024 | Ycanth |
| Helsinn Therapeutics (U.S.), INC. | $41.96 | 2022-2023 | Valchlor |
| Cipher Pharmaceuticals US LLC | $29.28 | 2025 | Natroba, Spinosad |
| Botanix Sb INC | $26.14 | 2025 | Sofdra |
| Paratek Pharmaceuticals, INC. | $23.81 | 2024 | Nuzyra |
| Lnhc, INC | $23.24 | 2025 | Zelsuvmi |
| Dermavant Sciences, INC. | $22.25 | 2024 | Vtama |
| Epi Health, LLC | $21.99 | 2022 | |
| Ucb, INC. | $21.67 | 2024 | Bimzelx |
| Organogenesis INC. | $18.87 | 2023 | Puraply |
| Csl Behring | $14.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Renzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.